VERA
Vera Therapeutics·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 3
Bearish signal 2
Consensus Rating "Strong Buy"
Ample Liquidity
Significant Net Income Decline
EPS Beats Expectation
RSI Overbought
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About VERA
Vera Therapeutics, Inc.
A biotech company developing novel immunomodulatory therapies for autoimmune diseases and cancer
8000 Marina Boulevard, Suite 120, Brisbane, California 94005
--
Vera Therapeutics, Inc., originally incorporated in Delaware in May 2016 under the name CDF Therapeutics, Inc., was renamed Vera Therapeutics, Inc., in April 2020. The company is an late-stage clinical biotechnology company focused on developing and commercializing translational therapies for patients with severe immune diseases. The company's lead product candidate, atacicept, is a self-administered fusion protein that blocks B lymphocyte stimulators and proliferation-inducing ligands with best-in-class potential for the treatment of IgA nephropathy.
Company Financials
EPS
VERA has released its 2025 Q3 earnings. EPS was reported at -1.26, versus the expected -1.13, missing expectations. The chart below visualizes how VERA has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
